Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Walter M. Stadler

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Stadler, Walter M.

Item TypeName
Concept Indoles
Academic Article Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
Academic Article A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Academic Article Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
Academic Article Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Academic Article Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.
Academic Article New therapeutic options for renal cell carcinoma.
Academic Article New targets, therapies, and toxicities: lessons to be learned.
Academic Article Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Academic Article Effective therapy for metastatic renal cancer, whither to now.
Academic Article Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Academic Article Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Academic Article Maturing of renal cancer therapeutics.
Academic Article First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.
Academic Article Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Academic Article Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Search Criteria
  • Indoles